Education
About Us
Working with TipRanks
Follow Us
Theravance Biopharma (TBPH)
NASDAQ:TBPH
Earnings Data
Report Date
Aug 11, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.25Last Year’s EPS
-0.34Same Quarter Last Year
Moderate Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: -9.29%
|Next Earnings Date:Aug 11, 2025
Earnings Call Sentiment|Positive
Theravance Biopharma reported strong financial and operational performance, with notable growth in YUPELRI sales and Trelegy milestones. Despite some challenges related to increased operating expenses and pending litigation, the company's overall financial health and strategic advancements position it well for future success.Company Guidance
During the Theravance Biopharma First Quarter 2025 Conference Call, the company provided various metrics and guidance. YUPELRI's net sales increased by 6% to over $58 million, driven by demand growth and favorable pricing. Hospital doses rose by 48% year-over-year. The company is advancing the Sypris trial, expecting to enroll the final patient by late summer with top-line data six months later. Theravance also highlighted the potential for a $25 million milestone if YUPELRI sales reach $250 million and a $7.5 million milestone for approval in China. Trelegy sales grew 14% globally, with expectations to achieve a $50 million milestone from Royalty Pharma in 2025. The quarter ended with $131 million in cash. The company anticipates a decline in R&D costs later in the year and expects cash burn to improve, excluding a one-time tax payment related to the Trelegy milestone.Strong Performance and Growth of YUPELRI
YUPELRI delivered solid results in the quarter with net sales increasing 6% to just over $58 million. Hospital doses increased 48% year on year, marking the strongest quarter launched to date in the hospital setting.
Trelegy Sales and Milestone Progress
GSK reported Trelegy global net sales up 14%, putting the company on track to achieve a $50 million milestone in 2025. Consensus estimates for 2025 and 2026 sales have increased by approximately $100 million since the last earnings call.
Financial Strength and Cash Position
Theravance ended the quarter with $131 million in cash and no debt, reflecting a strong financial position.
Advancement in Ampreloxetine Trials
Significant progress in the Sypris Phase III trial for ampreloxetine, with enrollment expected to complete by late summer and top-line data available approximately six months later.
Potential Long-term Value from Trelegy Royalties
Royalties from Trelegy expected to return in 2029 with significant value anticipated due to strong brand performance.
---
TBPH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TBPH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| May 08, 2025 | $9.90 | $8.98 | -9.29% |
| Feb 26, 2025 | $9.08 | $9.27 | +2.09% |
| Nov 12, 2024 | $8.91 | $9.68 | +8.64% |
| Aug 05, 2024 | $9.59 | $7.83 | -18.35% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Theravance Biopharma (TBPH) report earnings?
Theravance Biopharma (TBPH) is schdueled to report earning on Aug 11, 2025, TBA Not Confirmed.
What is Theravance Biopharma (TBPH) earnings time?
Theravance Biopharma (TBPH) earnings time is at Aug 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TBPH EPS forecast?
TBPH EPS forecast for the fiscal quarter 2025 (Q2) is -0.25.
---